FDA Approves mRNA Flu Shot for Seniors | Omaha News

FDA just approved Moderna’s new mRNA flu vaccine, mFlusiva, designed for adults 50 and older — a game-changer that could respond faster to flu mutations. While other vaccines hit shelves this fall, mFlusiva showed 27% fewer flu cases in 50-64-year-olds and strong immune response in seniors (with accelerated approval pending final study). Side effects were mild: sore arm, fever, headaches. After an initial setback, Moderna won back FDA support with unanimous panel approval — and it’s already rolling out soon. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a36e9a480db59096